A032101: A PHASE 2 TRIAL OF ADT INTERRUPTION IN PATIENTS RESPONDING EXCEPTIONALLY TO AR-PATHWAY INHIBITOR IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): A-DREAM

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

Rocky Mountain Regional VA Medical Center

Principal Investigator
Photograph of Jessica McDermott

Jessica McDermott

Study ID

Protocol Number: 22-1383

More information available at ClinicalTrials.gov: NCT05241860

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers